Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis
Authors' conclusion
Increased galectin-9 levels were related to tumor progression in CRDM, and galectin-9 was downregulated upon cancer treatment.
Study context
- Population
- Patients with DM, including cancer-related DM, vs healthy controls and tumour patients without DM
- Exposure
- Serum galectin-9 in DM (cancer-related DM (CRDM) subsets and non-CRDM) vs healthy controls and tumour patients without DM
- Outcome
- Serum galectin-9 (ng/ml)
Methodological detailsbiomarker study, ELISA, ROC analysis
- Biomarker study
- ELISA
- ROC analysis
Main finding
As reported in the abstract
P < 0.0001
Observational data: associations, not effects.
Further findings
Serum galectin-9 (ng/ml) by cancer status — new-CRDM vs stable-CRDM · higher in new-CRDM
P = 0.0288
| Outcome | P value |
|---|---|
| Serum galectin-9 (ng/ml) by cancer statusnew-CRDM vs non-CRDM · higher in new-CRDM | P = 0.0258 |
| Serum galectin-9 (ng/ml) by cancer statusnew-CRDM vs Tumour without DM · higher in new-CRDM | P < 0.0001 |
Correlation of galectin-9 with CDASI-A scores in DM
- Positive correlation, rs
- 0.3065
- P
- P = 0.0172
Serum galectin-9 (ng/ml) before vs after anti-cancer treatment in CRDM
- Before treatment
- 27.79 (17.04-41.43) ng/ml
- After treatment
- 13.88 (5.15-20.37) ng/ml
- Significant decrease
- P = 0.002
Prediction of cancer in DM: galectin-9 plus anti-TIF1-γ antibody
- AUC (highest predictive value), 95% CI 0.803-0.977
- 0.889
Original publication
Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis. Rheumatology (Oxford). Published 15 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →